Inovalon Holdings Inc. (NASDAQ:INOV) shares fell 2.6% during trading on Friday . The company traded as low as $19.08 and last traded at $19.10, with a volume of 325,549 shares trading hands. The stock had previously closed at $19.60.

A number of research firms recently commented on INOV. Morgan Stanley reiterated a “sell” rating and set a $16.00 price objective on shares of Inovalon Holdings in a research note on Sunday, May 8th. KeyCorp restated a “buy” rating and set a $26.00 target price on shares of Inovalon Holdings in a report on Sunday, May 22nd. Pacific Crest started coverage on shares of Inovalon Holdings in a report on Tuesday, March 29th. They set an “overweight” rating and a $26.00 target price for the company. Robert W. Baird cut shares of Inovalon Holdings from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $22.00 to $21.00 in a report on Thursday, April 21st. Finally, Zacks Investment Research cut shares of Inovalon Holdings from a “buy” rating to a “hold” rating in a report on Friday, July 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $21.71.

The company has a market capitalization of $2.93 billion and a P/E ratio of 52.74. The stock’s 50 day moving average price is $18.21 and its 200 day moving average price is $17.86.

Inovalon Holdings (NASDAQ:INOV) last announced its earnings results on Wednesday, May 4th. The company reported $0.05 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.03. During the same period in the previous year, the company posted $0.11 earnings per share. The business had revenue of $102.70 million for the quarter, compared to the consensus estimate of $97.96 million. The company’s revenue was up 9.7% on a year-over-year basis. On average, equities research analysts expect that Inovalon Holdings Inc. will post $0.56 earnings per share for the current fiscal year.

In other Inovalon Holdings news, CEO Keith R. Dunleavy purchased 30,000 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was acquired at an average cost of $16.68 per share, with a total value of $500,400.00. Following the completion of the purchase, the chief executive officer now directly owns 53,147 shares in the company, valued at approximately $886,491.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel L. Rizzo sold 43,577 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $20.02, for a total transaction of $872,411.54. Following the sale, the insider now directly owns 320,385 shares of the company’s stock, valued at $6,414,107.70. The disclosure for this sale can be found here.

Several large investors have bought and sold shares of the company. Eaton Vance Management acquired a new stake in Inovalon Holdings during the fourth quarter worth $4,908,000. Sei Investments Co. increased its stake in Inovalon Holdings by 69,028.7% in the fourth quarter. Sei Investments Co. now owns 257,850 shares of the company’s stock worth $4,383,000 after buying an additional 257,477 shares during the period. Russell Frank Co increased its stake in Inovalon Holdings by 29.1% in the fourth quarter. Russell Frank Co now owns 237,767 shares of the company’s stock worth $4,094,000 after buying an additional 53,651 shares during the period. Finally, Schroder Investment Management Group increased its stake in Inovalon Holdings by 384.4% in the fourth quarter. Schroder Investment Management Group now owns 223,800 shares of the company’s stock worth $3,805,000 after buying an additional 177,600 shares during the period.

Inovalon Holdings, Inc is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans, hospitals, physicians, patients, pharmaceutical companies and researchers. Through its datasets, integration technologies, predictive analytics and subject matter expertise, the Company delivers platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.